China-based Sanyou Biopharmaceuticals Co., Ltd has entered into a long-term strategic partnership with compatriot firm Dragon Sail Pharmaceutical. The collaboration aims to provide integrated and modular solutions covering biological drug research and development (R&D), Contract Development and Manufacturing Organization (CDMO) services, and commercial-scale production for the global biopharmaceutical industry.
Partnership Scope
The partnership will leverage the resources, expertise, and experience of both companies to conduct extensive collaboration in drug discovery, development, and CDMO services. Sanyou Biopharmaceuticals brings expertise in preclinical R&D services, including drug screening, pharmacology research, process development, and quality control for various biological drugs such as monoclonal antibodies, multi-specific antibodies, and ADC drugs. Dragon Sail Pharmaceutical contributes capabilities in pilot production, clinical sample production, scale-up process development, and commercial production of various biological drugs.
Company Profiles
Dragon Sail Pharmaceutical, established in 2016, is a CDMO/CMO enterprise providing one-stop R&D and production outsourcing services from sequence to IND, clinical sample production to BLA, and commercial production. The company has invested RMB 690 million (USD 103 million) in a manufacturing site, with the first phase being 32000L and the second phase reaching a scale of 62000L.
Sanyou Biopharmaceuticals has established an integrated R&D laboratory for antibody drugs exceeding 20,000 square meters, equipped with advanced facilities and more than 40 core innovation technology platforms. These platforms include innovative antibody drug discovery capabilities with trillion phage display antibody libraries, antibody drug optimization, cell line construction, upstream and downstream process development, preclinical R&D, and industrial development.-Fineline Info & Tech
